Cardiovascular Intervention and Therapeutics

, Volume 33, Issue 2, pp 116–124 | Cite as

Effects of caffeine on fractional flow reserve values measured using intravenous adenosine triphosphate

  • Masafumi Nakayama
  • Taishiro Chikamori
  • Takashi Uchiyama
  • Yo Kimura
  • Nobuhiro Hijikata
  • Ryosuke Ito
  • Mikio Yuhara
  • Hideaki Sato
  • Yuichi Kobori
  • Akira Yamashina
Original Article


We investigated the effects of caffeine intake on fractional flow reserve (FFR) values measured using intravenous adenosine triphosphate (ATP) before cardiac catheterization. Caffeine is a competitive antagonist for adenosine receptors; however, it is unclear whether this antagonism affects FFR values. Patients were evenly randomized into 2 groups preceding the FFR study. In the caffeine group (n = 15), participants were given coffee containing 222 mg of caffeine 2 h before the catheterization. In the non-caffeine group (n = 15), participants were instructed not to take any caffeine-containing drinks or foods for at least 12 h before the catheterization. FFR was performed in patients with more than intermediate coronary stenosis using the intravenous infusion of ATP at 140 μg/kg/min (normal dose) and 170 μg/kg/min (high dose), and the intracoronary infusion of papaverine. FFR was followed for 30 s after maximal hyperemia. In the non-caffeine group, the FFR values measured with ATP infusion were not significantly different from those measured with papaverine infusion. However, in the caffeine group, the FFR values were significantly higher after ATP infusion than after papaverine infusion (P = 0.002 and P = 0.007, at normal and high dose ATP vs. papaverine, respectively). FFR values with ATP infusion were significantly increased 30 s after maximal hyperemia (P = 0.001 and P < 0.001 for normal and high dose ATP, respectively). The stability of the FFR values using papaverine showed no significant difference between the 2 groups. Caffeine intake before the FFR study affected FFR values and their stability. These effects could not be reversed by an increased ATP dose.


Fractional flow reserve Caffeine Adenosine triphosphate Coronary artery disease Coronary circulation 



We thank Dr. Eisei Oda of Medical TOUKEI Corporation, Tokyo, Japan, for support with the statistical analysis. We also thank Dr. Edward F. Barroga, Associate Professor and Senior Medical Editor of the Department of International Communications at Tokyo Medical University for reviewing and editing the manuscript.

Compliance with ethical standards

Conflict of interest

This study was funded by Volcano Corporation (San Diego, CA, USA). The sponsor had no control over the interpretation, writing, or publication of this work. All authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Human rights and ethical standards

The study protocol was approved by the ethics committee of Toda Central General Hospital, and the study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients prior to their enrollment in this study.


  1. 1.
    Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek JKJJ, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996;334:1703–8.CrossRefPubMedGoogle Scholar
  2. 2.
    De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001.CrossRefPubMedGoogle Scholar
  3. 3.
    Pijls NH, Sels JW. Functional measurement of coronary stenosis. J Am Coll Cardiol. 2012;59:1045–57.CrossRefPubMedGoogle Scholar
  4. 4.
    Matsuo H, Kawase Y. FFR and iFR guided percutaneous coronary intervention. Cardiovasc Interv Ther. 2016;31:183–95.CrossRefPubMedGoogle Scholar
  5. 5.
    Pijls NH. Fractional flow reserve to guide coronary revascularization. Circ J. 2013;77:561–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Tarkin JM, Nijjer S, Sen S, Petraco R, Echavarria-Pinto M, Asress KN, et al. Hemodynamic response to intravenous adenosine and its effect on fractional flow reserve assessment: results of the Adenosine for the Functional Evaluation of Coronary Stenosis Severity (AFFECTS) study. Circ Cardiovasc Interv. 2013;6:654–61.CrossRefPubMedGoogle Scholar
  7. 7.
    De Bruyne B, Pijls NH, Barbato E, Bartunek J, Bech JW, Wijns W, et al. Intracoronary and intravenous adenosine 5′-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation. 2003;107:1877–83.CrossRefPubMedGoogle Scholar
  8. 8.
    Nakayama M, Saito A, Kitazawa H, Takahashi M, Sato M, Fuse K, et al. Papaverine-induced polymorphic ventricular tachycardia in relation to QTU and giant T-U waves in four cases. Intern Med. 2012;51:351–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Nakayama M, Tanaka N, Sakoda K, Hokama Y, Hoshino K, Kimura Y, et al. Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease. Circ J. 2015;79:530–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Mutha V, Asrar Ul Haq M, Van Gaal WJ. Effects of intravenous caffeine on fractional flow reserve measurements in coronary artery disease. Open Heart. 2014;1:e000060.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    McGeoch RJ, Oldroyd KG. Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology. Catheter Cardiovasc Interv. 2008;71:198–204.CrossRefPubMedGoogle Scholar
  12. 12.
    Aqel RA, Zoghbi GJ, Trimm JR, Baldwin SA, Iskandrian AE. Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease. Am J Cardiol. 2004;93:343–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Matsumoto H, Nakatsuma K, Shimada T, Ushimaru S, Mikuri M, Yamazaki T, et al. Effect of caffeine on intravenous adenosine-induced hyperemia in fractional flow reserve measurement. J Invasive Cardiol. 2014;26:580–5.PubMedGoogle Scholar
  14. 14.
    Johnson NP, Johnson DT, Kirkeeide RL, Berry C, De Bruyne B, Fearon WF, et al. Repeatability of fractional flow reserve despite variations in systemic and coronary hemodynamics. JACC Cardiovasc Interv. 2015;8:1018–27.CrossRefPubMedGoogle Scholar
  15. 15.
    American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64–71.CrossRefGoogle Scholar
  16. 16.
    Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.CrossRefPubMedGoogle Scholar
  17. 17.
    Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version. J Atheroscler Thromb. 2013;20:733–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Fukunaga AF, Flacke WE, Bloor BC. Hypotensive effects of adenosine and adenosine triphosphate compared with sodium nitroprusside. Anesth Analg. 1982;61:273–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Jeremias A, Filardo SD, Whitbourn RJ, Kernoff RS, Yeung AC, Fitzgerald PJ, et al. Effects of intravenous and intracoronary adenosine 5′-triphosphate as compared with adenosine on coronary flow and pressure dynamics. Circulation. 2000;101:318–23.CrossRefPubMedGoogle Scholar
  20. 20.
    Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD. Effects of adenosine on human coronary arterial circulation. Circulation. 1990;82:1595–606.CrossRefPubMedGoogle Scholar
  21. 21.
    Zheng XM, Williams RC. Serum caffeine levels after 24-hour abstention: clinical implications on dipyridamole (201)Tl myocardial perfusion imaging. J Nucl Med Technol. 2002;30:123–7.PubMedGoogle Scholar
  22. 22.
    Reyes E, Loong CY, Harbinson M, Donovan J, Anagnostopoulos C, Underwood SR. High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine. J Am Coll Cardiol. 2008;52:2008–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Fredholm BB. Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol. 1995;76:93–101.CrossRefPubMedGoogle Scholar
  24. 24.
    Lewis FW, Rector WG Jr. Caffeine clearance in cirrhosis: the value of simplified determinations of liver metabolic capacity. J Hepatol. 1992;14:157–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006;295:1135–41.CrossRefPubMedGoogle Scholar
  26. 26.
    Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol. 1997;37:693–703.CrossRefPubMedGoogle Scholar
  27. 27.
    Majd-Ardekani J, Clowes P, Menash-Bonsu V, Nunan TO. Time for abstention from caffeine before an adenosine myocardial perfusion scan. Nucl Med Commun. 2000;21:361–4.CrossRefPubMedGoogle Scholar
  28. 28.
    Belhassen B, Pelleg A. Electrophysiologic effects of adenosine triphosphate and adenosine on the mammalian heart: clinical and experimental aspects. J Am Coll Cardiol. 1984;4:414–24.CrossRefPubMedGoogle Scholar
  29. 29.
    Seo MK, Koo BK, Kim JH, Shin DH, Yang HM, Park KW, et al. Comparison of hyperemic efficacy between central and peripheral venous adenosine infusion for fractional flow reserve measurement. Circ Cardiovasc Interv. 2012;5:401–5.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Association of Cardiovascular Intervention and Therapeutics 2017

Authors and Affiliations

  • Masafumi Nakayama
    • 1
  • Taishiro Chikamori
    • 2
  • Takashi Uchiyama
    • 1
  • Yo Kimura
    • 1
  • Nobuhiro Hijikata
    • 1
  • Ryosuke Ito
    • 1
  • Mikio Yuhara
    • 1
  • Hideaki Sato
    • 1
  • Yuichi Kobori
    • 1
  • Akira Yamashina
    • 2
  1. 1.Cardiovascular CenterToda Central General HospitalTodaJapan
  2. 2.Department of CardiologyTokyo Medical UniversityTokyoJapan

Personalised recommendations